<DOC>
	<DOCNO>NCT01561781</DOCNO>
	<brief_summary>This study healthy volunteer assess pharmacokinetics ( PK ) Digoxin administer alone combination Vandetanib .</brief_summary>
	<brief_title>Study Healthy Volunteers Assess Pharmacokinetics ( PK ) Digoxin Administered Alone Combination With Vandetanib</brief_title>
	<detailed_description>A Phase I , Open-label , Single-center Study Assess Pharmacokinetics Digoxin Healthy Subjects When Administered Alone Combination Single Dose Vandetanib ( CAPRELSA ) 300 mg</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedures Volunteers must males female age 18 45 year weight least 50 kg body mass index ( BMI ) 18 30 kg/m2 , inclusive Females must negative pregnancy test screen admission study center . Females must lactate must nonchildbearing potential define postmenopausal documentation irreversible surgical sterilization . History clinically significant disease disorder gastrointestinal , hepatic , renal skin disease . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , Volunteers current smoker smoke used nicotine product within previous 6 month Screening blood pressure great 140/90 mmHg and/or rest heart rate le 45 beat per minute ( repeat test allow Investigator 's discretion Clinically significant abnormal12lead ECG assess Investigator , QTcF interval great 450 m Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) , positive screen drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>vandetanib</keyword>
	<keyword>digoxin</keyword>
</DOC>